Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors
J. Clin. Invest. Philipp Beckhove, et al. 114:67 doi:10.1172/JCI20278 [Go to this article.]

Figure 1
TA specificity and function of BM memory T cells from breast cancer patients. (A) T cells were stained with tetramers containing HLA-A2 and the MUC1 peptide LLLLTVLTV or the irrelevant HIV peptide SLYNTVATL. Representative data are shown. Blue, low density of cells; yellow, high density of cells. (B and C) Frequencies of MUC1- or Her-2/neu–specific CD8⁺ T cells from BM and PB of patients (P) and healthy donors (HD). Maximal levels of tetramer-binding CD8⁺ T cells from healthy donors are depicted by dotted lines. Frequencies of HIV-specific CD8⁺ T cells from BM and PB of nine breast cancer patients are shown. Maximum levels of nonspecific bindings are depicted by solid lines. (D) Accumulative data for MUC1- and Her-2/neu–binding CD8⁺ T cells expressing memory markers (seven and six patients, respectively). *P < 0.0001, memory versus naive cells; *P < 0.0001, EM versus CM cells. (E) Frequencies of Her-2/neu–specific BM T cells from patients or healthy donors, measured by IFN-γ ELISPOT after stimulation by DCs pulsed with the Her-2/neu peptide KIFGSLAFL. (F) MUC1-specific cytotoxicity of BM T cells. Patient (filled squares and filled triangles) or donor (open circles) cells were stimulated for 5 days with DCs pulsed with the MUC1 peptide LLLLTVLTV. HLA-A2⁺ T2 target cells were loaded with LLLLTVLTV (filled squares, open circles) or SLYNTVATL (filled triangles) peptides. X axis represents effector/target (E/T) ratios.